|Dr. Howard J. Verrico M.D.||Founder, Chairman, Chief Exec. Officer and Sec.||158.62k||N/A||56|
|Mr. Christopher D. Hopton C.G.A.||Chief Financial Officer and Director||149.12k||N/A||51|
|Dr. Géraldine Deliencourt-Godefroy Ph.D.||Chief Scientific Officer and Director||193.36k||N/A||N/A|
|Ms. Michelle Seltenrich MBA||VP of Operations||N/A||N/A||N/A|
|Ms. Aleksandra Kasikovic MSc||Mang. of Commercial Devel.||N/A||N/A||N/A|
Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.
Sirona Biochem Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.